Ireland
--:--IST
Latest
Clinical Trials in Portugal / NCT07510776
Recruiting Observational

UP STUDY - Decipher Persistent Critical Illness Through in Deep Clinical Phenotyping.

NCT07510776 · tracked via the Priya Life Science Portugal tracker
Phase
Observational
Started
2025-01-13
Last updated
2026-04-13

Condition(s) studied

Critical IllnessRecovery OutcomesCritical Care, Intensive CareCritical CareCritical Care Medicine

Study summary

Persistent Critical Illness (PCI) is a condition that affects some patients who remain in the Intensive Care Unit (ICU) for a long time, usually more than 10-14 days. It is estimated to occur in 5-20% of critically ill patients. A recent Portuguese study found that more than 14% of ICU patients stayed longer than 14 days. PCI is often associated with ongoing need for life support, such as mechanical ventilation or medications to maintain blood pressure. However, patients may also experience severe muscle weakness, repeated infections, or other complications, which makes this group very diverse.

One of the main risk factors for prolonged ICU stay is sepsis, a severe infection that affects the whole body. Other factors-such as prior health conditions, use of corticosteroids, sedation practices, early versus late mobilization, fluid and antibiotic management, and delirium treatment-may also influence the development and course of PCI.

This study aims to identify different clinical patterns ("clusters") among critically ill patients who remain in the ICU for more than 10 days. Patients will be followed until hospital discharge, and up to one year if data are available. Understanding these different patterns will help develop more personalized and effective care strategies for each patient profile.

The study is a multicenter retrospective cohort including adult patients (≥18 years) admitted to participating ICUs for more than 5 days between 2021 and 2023. Data collected will include demographic, clinical, and laboratory information, details of organ support (such as mechanical ventilation or vasopressors), medications, nutrition, and rehabilitation practices.

Statistical and machine learning methods will be used to identify groups of patients with similar clinical trajectories and to assess how these groups are related to outcomes such as survival, recovery of organ function, or long-term disability.

Expected results are the identification of distinct clinical clusters of PCI that combine clinical and laboratory data, and the development of tailored management strategies to improve recovery and outcomes for patients with PCI.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patients aged 18 years or older; * ICU length of stay equal to or greater than 5 days. Exclusion Criteria: * Patients with an ICU stay \< 5 days; * Patients discharged from the ICU early due to lack of ward availability, rather than clinical recovery; * Patients who do not survive the early phase of critical illness (i.e., early ICU deaths).

Primary outcome measure(s)

Trial sites (7)

FacilityCityRegionStatus
Centro Hospitalar de São João / ULS São João Lisbon Lisbon District Recruiting
Hospital de Vila Franca de Xira / ULS Estuário do Tejo Lisbon Lisbon District Recruiting
Hospital Garcia de Orta / ULS Almada-Seixal Lisbon Lisbon District Recruiting
Hospital Prof. Doutor Fernando Fonseca / ULS Amadora -Sintra Lisbon Lisbon District Recruiting
Hospital Santa Maria / ULS Santa Maria Lisbon Lisbon District Recruiting
Hospital São Francisco Xavier / Centro Hospitalar de Lisboa Ocidental Lisbon Lisbon District Recruiting
Hospital de VIla Nova de Gaia-Espinho / ULS Gaia e Espinho Vila Nova de Gaia Porto District Not Yet Recruiting

More Lisbon Academic Medical Center - Centro Académico de Medicina de Lisboa trials in Portugal

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07510776 on ClinicalTrials.gov ↗ ← All trials in Portugal